Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Glycotex has completed patient enrollment in a Phase IIa study evaluating the effect of GLYC-101 on wound closure in patients undergoing carbon dioxide laser skin resurfacing.
Subscribe to our email newsletter
The randomized, double-blind, placebo-controlled clinical study in Beverly Hills, California has enrolled 12 patients undergoing laser skin ablation. In addition to assessing safety endpoints, the study is investigating efficacy endpoints, among them the promotion of wound healing and cosmetic outcomes.
The strategic priorities for GLYC-101 include wound healing following laser ablation, burn wounds, surgical wounds, venous ulcers and diabetic ulcers.